Royal London Asset Management LTD Neurocrine Biosciences Inc Transaction History
Royal London Asset Management LTD
- $39.8 Billion
- Q4 2024
A detailed history of Royal London Asset Management LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Royal London Asset Management LTD holds 51,533 shares of NBIX stock, worth $5.96 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
51,533
Previous 51,533
-0.0%
Holding current value
$5.96 Million
Previous $5.93 Million
18.58%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
95.2MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.64 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$565 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$349 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$293 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...